Saturday 17 October 2026
Export PHIO’s income statement to Excel — free account
Phio Pharmaceuticals Corp.
PHIO Healthcare Biotechnology
In the quarter to June 2026, EPS grew 20.0% and free cash flow fell 58.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.87
0.06
−6.45%
Follow PHIO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (113.71%) | (76.36%) | (69.95%) | (107.58%) |
+8 more TTM periods Free account |
|
| (100.78%) | (70.87%) | (63.90%) | (91.57%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(102.40%) | (66.41%) | (43.17%) | (80.83%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.05) | (0.92) | (1.34) | (1.33) | |
Free Cash Flow |
(12.21) | (10.71) | (7.99) | (7.27) | |
Capital Expenditures |
0.00 | (0.01) | (0.01) | 0.00 | |
| Other line items | |||||
Cash ROIC |
(47.68%) | (31.99%) | (19.41%) | (35.41%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.95 | 0.98 | 0.92 | 0.91 | |
Depreciation/Fixed assets |
0.56 | 0.40 | 0.27 | 0.25 | |
Capex/Depreciation |
(0.80) | (1.75) | (4.00) | (1.33) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.05) | (0.92) | (1.33) | (1.33) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates